Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Review Improvements Not Expected Until FY 2005 Under MDUFMA

This article was originally published in The Silver Sheet

Executive Summary

MEDICAL DEVICE USER FEES are expected to lead to a 25% reduction in premarket review times at the end of five years. Under the "Medical Device User Fee and Modernization Act," signed by President Bush Oct. 26, manufacturers will pay FDA a range of fees – from $154,000 for PMA reviews to $2,187 for 510(k)s – in return for the agency’s commitment to meet increasingly strict cycle review and decision goals as the program matures. Fees will fund a number of review-related activities, including pre-approval inspections, clinical trial monitoring and standards development. The Center for Devices and Radiological Health has assigned various teams to begin implementing the new program and to assess how user fees will affect operations across the center

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel